Mercedes Mitjavila, Paula Jimenez-Fonseca, Pilar Belló, Virginia Pubul, Juan Carlos Percovich, Amparo Garcia-Burillo, Jorge Hernando, Javier Arbizu, Emilia Rodeño, Montserrat Estorch, Belén Llana, Maribel Castellón, Lina García-Cañamaque, Pablo Gajate, Maria Carmen Riesco, Maria Begoña Miguel, David Balaguer-Muñoz, Ana Custodio, Juana María Cano, Alexandra Repetto, Pilar Garcia-Alonso, Maria Angustias Muros, Jose Luis Vercher-Conejero, Alberto Carmona-Bayonas
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [177 Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled...
March 6, 2023: European Journal of Nuclear Medicine and Molecular Imaging